Development of a hydrogen peroxide-inactivated vaccine that protects against viscerotropic yellow fever in a non-human primate model.


Journal

Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894

Informations de publication

Date de publication:
16 Jul 2024
Historique:
received: 13 11 2023
revised: 06 03 2024
accepted: 19 06 2024
medline: 18 7 2024
pubmed: 18 7 2024
entrez: 17 7 2024
Statut: ppublish

Résumé

Yellow fever virus (YFV) is endemic in >40 countries and causes viscerotropic disease with up to 20%-60% mortality. Successful live-attenuated yellow fever (YF) vaccines were developed in the mid-1930s, but their use is restricted or formally contraindicated in vulnerable populations including infants, the elderly, and people with compromised immune systems. In these studies, we describe the development of a next-generation hydrogen peroxide-inactivated YF vaccine and determine immune correlates of protection based on log neutralizing index (LNI) and neutralizing titer-50% (NT

Identifiants

pubmed: 39019010
pii: S2666-3791(24)00369-0
doi: 10.1016/j.xcrm.2024.101655
pii:
doi:

Substances chimiques

Hydrogen Peroxide BBX060AN9V
Vaccines, Inactivated 0
Yellow Fever Vaccine 0
Antibodies, Neutralizing 0
Antibodies, Viral 0
Vaccines, Attenuated 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101655

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests Oregon Health & Science University (OHSU), M.K.S., E.H., and I.J.A. have a financial interest in Najít Technologies, Inc., a company that may have a commercial interest in the results of this research and technology. This potential individual and institutional conflict of interest has been reviewed and managed by OHSU and Najít Technologies, Inc. M.S.D. is a consultant or member of a scientific advisory board for InBios, Ocugen, Vir Biotechnology, Topspin Therapeutics, and Moderna. The Diamond laboratory has received unrelated funding support in sponsored research agreements from Emergent BioSolutions, Moderna, and Vir Biotechnology. I.J.A. and E.A.P. are inventors on US patent no. 10,744,198 entitled “Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production” and US patent nos. 11,141,475 and 11,633,470 entitled “Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process.” M.K.S. and E.H. are inventors on US patent nos. 8,124,397 and 8,716,000 entitled “Inactivating pathogens with oxidizing agents for vaccine production.” No writing assistance was utilized in the production of this manuscript.

Auteurs

Ian J Amanna (IJ)

Najít Technologies, Inc., Beaverton, OR 97006, USA.

Archana Thomas (A)

Division of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.

Flora Engelmann (F)

Department of Microbiology, Immunology and Molecular Genetics, University of Kentucky, College of Medicine, Lexington, KY 40506, USA.

Erika Hammarlund (E)

Division of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.

Hans-Peter Raué (HP)

Division of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.

Adam L Bailey (AL)

Department of Pathology & Laboratory Medicine, University of Wisconsin - Madison, Madison, WI 53706, USA.

Elizabeth A Poore (EA)

Najít Technologies, Inc., Beaverton, OR 97006, USA.

Benjamin K Quintel (BK)

Najít Technologies, Inc., Beaverton, OR 97006, USA.

Anne D Lewis (AD)

Division of Comparative Medicine, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.

Michael K Axthelm (MK)

Division of Pathobiology & Immunology, Oregon National Primate Research Center, and The Vaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR 97006, USA.

Amanda L Johnson (AL)

Division of Comparative Medicine, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.

Lois M A Colgin (LMA)

Division of Comparative Medicine, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.

Michael S Diamond (MS)

Departments of Medicine, Molecular Microbiology, Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.

Ilhem Messaoudi (I)

Department of Microbiology, Immunology and Molecular Genetics, University of Kentucky, College of Medicine, Lexington, KY 40506, USA.

Mark K Slifka (MK)

Division of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA. Electronic address: slifkam@ohsu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH